SenzaGen AB (STO:SENZA)

Market Cap	148.24M -19.0%
Revenue (ttm)	61.05M +9.3%
Net Income	-9.25M
EPS	-0.31
Shares Out	32.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,332
Open	4.600
Previous Close	4.640
Day's Range	4.400 - 4.600
52-Week Range	4.280 - 6.840
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About SenzaGen AB

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 34
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SENZA

Financial Performance

In 2025, SenzaGen AB's revenue was 57.97 million, an increase of 0.48% compared to the previous year's 57.70 million. Losses were -11.59 million, 3.29% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error